© B2Bioworld 2017 North Korea emerging marketEmerging Market North Korea: Bringing medical diagnostics to an as yet closed off economy

July 2017. South Korea’s Northern neighbour is rarely thought as having characteristics of a developed market, nor is it arguably seen in transition to a liberal economy. What can be learned to approach a market with major risks to implode after a nuclear strike, or acquiring a stake in an economy which might become another emerging Asian market such as Chinese Shenzhen Province, or Vietnam

David Dolinger, a veteran in the molecular diagnostics industry and in NGO arenas shares his experience of working in Korea. He provides insights doing business with the North Korea.

If you like to read this article, you can purchase it now

Please notice, If you order by email from an organisation - for-profit or nonprofit alike - you must buy an organisation sharing license and cannot buy an individual license. However the organisation sharing license entitles you to share the article with up to four other individuals - provided you adhere to the Terms and Conditions which you agree with when purchasing articles of B2Bioworld.

Read Now - Please select your license (Prices incl. 7% VAT)
4 pages free of advertisement

Article free of advertisement
- Includes current overviews on EU humanitarian aid (organisations, aid volumes, activity domains) in North Korea 2004-2015; Recent data on tuberculosis/AIDS cases, fundings, success rates, and other context information added by B2Bioworld.

Full Company / Organisation License enquire here

Back to section

Related Editorial Articles

B2Bioworld offers you background information

Opening up Emerging Markets for Rapid Diagnostics and Point-of-Care Assays

Roche Ethiopia: Build-up of an emerging market

The Laboratory Furniture Market
- Assessment and Outlook

We need the users, and users have to adopt it
A Global View on Interconnectivity, Quality, Harmonisation of Standards of Laboratory Automation and Biomanufacturing by Oscar-Werner Reif, Member of Board Sartorius Stedim Biotech S.A.

Pharma Boost for Red Cross/Red Crescent’s Community Disease Prevention Programme

Diagnostic Microfluidics: Sample In – Results Out?
Marc Feiglin, past Chief Technology Officer Life Sciences at Tecan on strengths and weaknesses of electrowetting development, weaknesses of competitors like Illumina. Prospects of clinical microfluidics

Eurofins helps Pasteur de Lille out of the doldrums

Seiko Epson and its Business Perspectives
Independent assessment. Includes an interview with Minoru Usui, CEO of the company

Emerging Market Iran: How to shield your medical diagnostics assets